PerformanceHigh Risk
Follistatin 344
Also known as: FST-344, Follistatin
- Half-life:
- ~24-36 hours
Administration Routes
intramuscular injection
PeptideBase provides educational research tools and provider discovery. It does not provide medical advice, diagnosis, treatment, prescribing guidance, or dosing instructions. Consult a qualified healthcare professional before making health decisions.
Mechanism of Action
Binds and neutralizes myostatin (GDF-8) and activin; removes the natural brake on muscle growth allowing supraphysiological hypertrophy
A myostatin inhibitor that removes the natural limit on muscle growth. Produces dramatic increases in muscle mass and strength by blocking TGF-β family proteins.
Primary Research Areas
- myostatin inhibition
- muscle hypertrophy
- strength gains
- fat reduction
Risk Profile
High Risk
Higher risk profile in research contexts. Consult a healthcare professional before use.
Regulatory Status
Research OnlyNot Evaluated by FDA
Myostatin inhibitor. No FDA approval. Gene therapy forms in early trials but recombinant protein is a research chemical. WADA prohibited. No NDA or IND for peptide form.
Regulatory status reflects publicly available information and may change. This is not legal or medical advice.